Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	80319
Country	China

Received	2022-09-22 16:14
Peer-Review Started	2022-09-22 16:16
To Make the First Decision
Return for Revision	2022-11-30 22:45
Revised	2022-12-18 14:40
Second Decision	2023-01-05 03:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-01-05 19:49
Articles in Press	2023-01-05 19:49
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-01-13 07:25
Typeset the Manuscript	2023-02-07 06:41
Publish the Manuscript Online	2023-02-15 00:44

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Review
Article Title	“Cold” colorectal cancer faces a Bottleneck in immunotherapy
Manuscript Source	Invited Manuscript
All Author List	Jia-Liang Liu, Ming Yang, Jun-Ge Bai, Zheng Liu and Xi-Shan Wang
ORCID	Author(s) ORCID Number Zheng Liu http://orcid.org/0000-0002-8831-0761 Xi-Shan Wang http://orcid.org/0000-0002-1675-5083
Funding Agency and Grant Number
Corresponding Author	Zheng Liu, FASCRS, MD, PhD, Professor, Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. zheng.liu@cicams.ac.cn
Key Words	Immunotherapy; “Cold” colorectal cancer; Immune checkpoint inhibitors
Core Tip	Immune checkpoint inhibitors (ICIs) are usually produced by antibodies, and their effectiveness relies on the antitumor effects of immune cells (especially T cells). Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. only a limited number of patients are currently benefiting from ICIs owing to limitations such as individual differences and low response rates. In this review, we discuss the classification and differences between hot and cold CRC and the current status of research on cold CRC, and summarize the treatment strategies and challenges of immunotherapy for cold CRC.
Publish Date	2023-02-15 00:44
Citation	Liu JL, Yang M, Bai JG, Liu Z, Wang XS. “Cold” colorectal cancer faces a Bottleneck in immunotherapy. World J Gastrointest Oncol 2023; 15(2): 240-250
URL	https://www.wjgnet.com/1948-5204/full/v15/i2/240.htm
DOI	https://dx.doi.org/10.4251/wjgo.v15.i2.240

Full Article (PDF)	WJGO-15-240.pdf
Full Article (Word)	WJGO-15-240.docx
Manuscript File	80319-Review-Filipodia.docx
Answering Reviewers	80319-Answering reviewers.pdf
Audio Core Tip	80319-Audio core tip.wav
Conflict-of-Interest Disclosure Form	80319-Conflict-of-interest statement.pdf
Copyright License Agreement	80319-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	80319-Language certificate.pdf
Peer-review Report	80319-Peer-review(s).pdf
Scientific Misconduct Check	80319-Bing-Wang JJ-2.png
Scientific Editor Work List	80319-Scientific editor work list.pdf